{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:44:13Z","timestamp":1792107853175,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtho.2024.09.1437","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T19:35:19Z","timestamp":1727552119000},"page":"39-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee"],"prefix":"10.1016","volume":"20","author":[{"given":"Badr Id","family":"Said","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahed N.","family":"Badiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bezjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.M.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Przybysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Putora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Munoz-Schuffenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xu-Welliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-8044","authenticated-orcid":false,"given":"Stephen G.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.09.1437_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.radonc.2020.04.047","article-title":"Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab","volume":"149","author":"Offin","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdj117","article-title":"Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients","volume":"17","author":"Auperin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdn559","article-title":"Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study","volume":"20","author":"De Ruysscher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.clon.2020.05.001","article-title":"Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic","volume":"32","author":"Faivre-Finn","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jtho.2024.09.1437_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cllc.2014.08.002","article-title":"Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature","volume":"16","author":"Kaster","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.09.1437_bib6","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aaf26a","article-title":"The linear quadratic model: usage, interpretation and challenges","volume":"64","author":"McMahon","year":"2018","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.23.00627","article-title":"Selective personalized radioimmunotherapy for locally advanced non-small-cell lung cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib8","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jamaoncol.2021.3186","article-title":"Accelerated hypofractionated image-guided vs conventional radiotherapy for patients with stage II\/III non-small cell lung cancer and poor performance status: a randomized clinical trial","volume":"7","author":"Iyengar","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.5603\/RPOR.a2021.0095","article-title":"Short term clinical outcomes of accelerated hypofractionated radiotherapy in inoperable non-small cell lung cancer patients","volume":"26","author":"Aye","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.jtho.2024.09.1437_bib10","first-page":"842","article-title":"A\u00a0randomized study comparing two hypofractioned 3-D conformal radiotherapy for stage IIIb\u2013IV non small cell lung cancer","volume":"25","author":"Zygogianni","year":"2020","journal-title":"J\u00a0BUON"},{"key":"10.1016\/j.jtho.2024.09.1437_bib11","article-title":"Outcomes of hypofractional tomotherapy in patients with stage III nonsmall cell lung cancer who are not eligible for surgery or concurrent chemoradiation","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jtho.2024.09.1437_bib12","first-page":"885","article-title":"A\u00a0phase I study of hypofractionated carbon-ion radiotherapy for stage III non-small cell lung cancer","volume":"38","author":"Saitoh","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2024.09.1437_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clon.2017.10.010","article-title":"A\u00a0phase II toxicity end point trial (ICORG 99\u201309) of accelerated dose-escalated hypofractionated radiation in non-small cell lung cancer","volume":"30","author":"Cagney","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jtho.2024.09.1437_bib14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/cncr.29195","article-title":"A\u00a0prospective nonrandomized phase I\/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC)","volume":"121","author":"Takahashi","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2024.09.1437_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/0973-1482.157332","article-title":"Prospective study of special stage II (T2b-3N0M0) non-small-cell lung cancer treated with hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy","volume":"11","author":"Zhang","year":"2015","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.jtho.2024.09.1437_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2015.05.004","article-title":"Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: phase 1 dose escalation trial","volume":"93","author":"Westover","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2024.09.1437_bib17","first-page":"5693","article-title":"Hypofractionated image-guided radiation therapy (3Gy\/fraction) in patients affected by inoperable advanced-stage non-small cell lung cancer after long-term follow-up","volume":"35","author":"Agolli","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2024.09.1437_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijrobp.2013.03.035","article-title":"Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer","volume":"86","author":"Gomez","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2024.09.1437_bib19","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2011.01.022","article-title":"A\u00a0phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer","volume":"98","author":"Zhu","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoncol.2023.6033","article-title":"Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer: a nonrandomized controlled trial","volume":"10","author":"Wu","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109492","article-title":"(18)F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2022.03.005","article-title":"Chemoradiation with hypofractionated proton therapy in stage II\u2013III non-small cell lung cancer: a proton collaborative group phase 2 trial","volume":"113","author":"Hoppe","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2024.09.1437_bib24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijrobp.2022.01.012","article-title":"Phase I study of accelerated hypofractionated proton therapy and chemotherapy for locally advanced non-small cell lung cancer","volume":"113","author":"Contreras","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2024.09.1437_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.prro.2021.06.004","article-title":"Hypofractionated intensity modulated radiation therapy with concurrent chemotherapy in locally advanced non-small cell lung cancer: a phase II prospective clinical trial (GASTO1011)","volume":"11","author":"Qiu","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.prro.2020.09.001","article-title":"Phase II study: the outcome of hypofractionated involved-field radiation therapy with concurrent chemotherapy for the treatment of locally advanced non-small cell lung cancer","volume":"11","author":"Katsuta","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.09.1437_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2019.10.008","article-title":"Local and regional treatment response by 18FDG-PET-CT-scans 4weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC","volume":"143","author":"van Diessen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijrobp.2020.03.015","article-title":"Hypofractionated proton therapy with concurrent chemotherapy for locally advanced non-small cell lung cancer: a phase 1 trial from the University of Florida and proton collaborative group","volume":"107","author":"Hoppe","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2024.09.1437_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.radonc.2020.04.033","article-title":"Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: a phase I\/II study","volume":"148","author":"Glinski","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13014-019-1317-x","article-title":"Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up","volume":"14","author":"Parisi","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijrobp.2018.01.046","article-title":"Phase 1 study of accelerated hypofractionated radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: CALGB 31102 (alliance)","volume":"101","author":"Urbanic","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2024.09.1437_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COC.0000000000000140","article-title":"Dose-escalated hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy for inoperable or unresectable non-small cell lung cancer","volume":"40","author":"Kim","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.radonc.2016.02.011","article-title":"Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab","volume":"118","author":"Walraven","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib35","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150966","article-title":"Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a phase II randomized study","volume":"89","author":"Roy","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12885-016-2314-1","article-title":"Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy\/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial","volume":"16","author":"Ren","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2024.09.1437_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7785\/tcrt.2012.500375","article-title":"Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer","volume":"13","author":"Zhu","year":"2014","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jtho.2024.09.1437_bib38","first-page":"198","article-title":"High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy\/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study","volume":"8","author":"Liu","year":"2013","journal-title":"Radiat"},{"key":"10.1016\/j.jtho.2024.09.1437_bib39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1748-717X-8-201","article-title":"Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy\/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial","volume":"8","author":"Lin","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.radonc.2019.07.008","article-title":"Estimation of the alpha\/beta ratio of non-small cell lung cancer treated with stereotactic body radiotherapy","volume":"142","author":"Klement","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.09.1437_bib42","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib43","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2024.09.1437_bib44","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG oncology RTOG 0415: a randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib45","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib46","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.09.1437_bib47","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib48","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.09.1437_bib49","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.09.1437_bib50","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.2217\/fon-2021-0952","article-title":"DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy","volume":"17","author":"Filippi","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib51","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamaoncol.2024.1841","article-title":"Long-term prospective outcomes of intensity modulated radiotherapy for locally advanced lung cancer: a secondary analysis of a randomized clinical trial","volume":"10","author":"Chun","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib52","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.09.1437_bib53","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.09.1437_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fonc.2017.00201","article-title":"The potential of heavy-ion therapy to improve outcomes for locally advanced non-small cell lung cancer","volume":"7","author":"Chun","year":"2017","journal-title":"Front Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424023530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424023530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:35:26Z","timestamp":1767231326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424023530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1556086424023530"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1437","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}